Article
Biochemistry & Molecular Biology
Shenglin Wang, Yunqing Wang, Zhen Huang, Hongxiang Wei, Xinwen Wang, Rongkai Shen, Wenbin Lan, Guangxian Zhong, Jianhua Lin
Summary: This study confirms the moderate anti-tumor effects of gefitinib on osteosarcoma, via suppression of the PI3K/Akt and ERK pathways to reduce cell proliferation and migration. Combined treatment with stattic further enhances the inhibitory effects of gefitinib, reducing cell invasion and promoting apoptosis.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2021)
Article
Biochemistry & Molecular Biology
Hung-Pei Tsai, Chien-Ju Lin, Chieh-Hsin Wu, Yi-Ting Chen, Ying-Yi Lu, Aij-Lie Kwan, Ann-Shung Lieu
Summary: This study found that EGFR-positive expression is associated with reduced overall survival in brain astrocytomas, while p53 expression does not show significant correlation with survival. In patients with low p53 expression, EGFR-positive staining is associated with worse survival. The combined expression of EGFR and p53 may have prognostic significance in astrocytomas.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2022)
Article
Oncology
Seo Yun Moon, Heejin Lee, Seoree Kim, Ji Hyung Hong, Sang Hoon Chun, Hee Yeon Lee, Keunsoo Kang, Ho Shik Kim, Hye Sung Won, Yoon Ho Ko
Summary: The EGFR and Src-mediated STAT3 signaling pathway is activated in tamoxifen-resistant breast cancer cells, and inhibition of STAT3 may be a potential target for overcoming tamoxifen resistance. Increase in nuclear p21(Cip1) may play a key role in STAT3 inhibitor-induced cell death in tamoxifen-resistant cells.
Article
Biochemistry & Molecular Biology
Yajun Li, Kaisa Cui, Qiang Zhang, Xu Li, Xingrong Lin, Yi Tang, Edward Prochownik, Youjun Li
Summary: This study identified the amplified and over-expressed FBXL6 in colorectal cancer patients, which is highly correlated with poor prognosis, and revealed its mechanism in suppressing p53 signaling by targeting phospho-p53 for degradation. The feed-forward loop of FBXL6-p53, where p53 transcriptionally suppresses FBXL6 expression, might serve as a potential therapeutic target for CRC treatments.
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Chemistry, Medicinal
Ru Wang, Ting-Ting Du, Wen-Qiang Liu, Yi-Chen Liu, Ya-Dong Yang, Jin-Ping Hu, Ming Ji, Bei-Bei Yang, Li Li, Xiao-Guang Chen
Summary: By designing and testing the inhibitory effects of compounds on the STAT3 pathway, researchers have successfully developed a novel selective STAT3 inhibitor that can inhibit STAT3 phosphorylation, translocation, and downstream gene transcription. This compound has demonstrated anti-proliferative and apoptotic effects on STAT3-overactivated cancer cells and exhibited promising anti-tumor efficacy in a mouse model.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Yu Ruofei, Bai Hua, Li Tangai, Gao Bingyu, Han Jiefei, Chang Geyun, Zhang Pei, Fei Kailun, He Xiran, Wang Jie
Summary: In patients with EGFR-mutant lung adenocarcinoma, those with TP53 mutations had significantly shorter progression-free survival and overall survival. TP53 mutations in different exons influence the response and prognosis of patients treated with gefitinib. Patients with mutations in TP53 exons 6 and 7 had worse survival outcomes.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Huang Chen, Wenbo Zhou, Aiwu Bian, Qiansen Zhang, Ying Miao, Xuan Yin, Jiangnan Ye, Shifen Xu, Chaowen Ti, Zhenliang Sun, Jianghua Zheng, Yihua Chen, Mingyao Liu, Zhengfang Yi
Summary: This study identifies a novel drug called WB436B as a selective STAT3 inhibitor for the treatment of pancreatic cancer. WB436B effectively inhibits tumor growth and metastasis, providing hope for the treatment of pancreatic cancer.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Guojin Zhang, Yuntai Cao, Jing Zhang, Zhiyong Zhao, Wenjuan Zhang, Junlin Zhou
Summary: The study analyzed the relationship between dual-energy spectral CT and EGFR mutation status in patients with lung adenocarcinoma. Significant differences were observed in sex and smoking history according to EGFR mutation status. The quantitative parameters of spectral CT showed significant differences between EGFR mutant and wild-type groups, with the combination of these parameters providing the best diagnostic performance for determining EGFR mutation status.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Review
Oncology
Jane E. Rogers, Kohei Yamashita, Matheus Sewastjanow-Silva, Allison Trail, Rebecca E. Waters, Jaffer Ajani
Summary: Human epidermal growth factor receptor-2 (HER2) is a well-known cancer target with various therapies available. However, the response and effectiveness of HER2-targeted agents differ among different tumor types, including gastric adenocarcinomas (GACs). GACs exhibit heterogeneity in HER2 expression, both within and between tumors, which poses challenges in assessing the efficacy of HER2-targeted agents. The recent approval of trastuzumab deruxtecan, an antibody drug conjugate, for refractory HER2-positive advanced GAC patients shows promise. Ongoing research aims to understand resistance patterns and intra-tumor heterogeneity to improve treatment outcomes. This review discusses the current status of HER2-targeted therapy in GACs and explores new therapies under investigation.
Article
Cardiac & Cardiovascular Systems
Aritoshi Hattori, Takeshi Matsunaga, Mariko Fukui, Kazuya Takamochi, Kenji Suzuki
Summary: The study evaluated the prognostic role of EGFR mutation in early-stage invasive lung adenocarcinoma, finding that tumor subtype and pathological staging were predictive factors for recurrence-free survival. In the subset of clinical T1c/T2a lung adenocarcinomas, EGFR mutation and advanced pathological staging independently predicted worse RFS.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2022)
Article
Oncology
Ji-wen Huo, Tian-you Luo, Le Diao, Fa-jin Lv, Wei-dao Chen, Rui-ze Yu, Qi Li
Summary: This study shows that combined models incorporating radiomics signatures, clinical, and CT morphological features can help predict EGFR-mutation subtypes in lung adenocarcinoma, contributing to individualized treatment for patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Ning Liu, Lingnan Zheng, Min Yu, Shuang Zhang
Summary: This case report describes a patient with EGFR-mutant lung adenocarcinoma coexisting with pulmonary tuberculosis. The patient was initially diagnosed with pneumonia-like pulmonary adenocarcinoma and later confirmed to have active tuberculosis. The patient received a combination therapy of gefitinib and anti-TB treatment, leading to stable disease status and survival.
Article
Biochemistry & Molecular Biology
Barbara Schreier, Virginie Dubourg, Stefanie Huebschmann, Sindy Rabe, Sigrid Mildenberger, Michael Gekle
Summary: The study reveals that EGFR and AT1R synergistically regulate gene expression, leading to qualitative, quantitative, and temporal changes, potentially impacting cell stress and vascular biology. Synergistic activation of SRF via distinct pathways and transcription factors AP1 and EGR plays a key role in this process.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Oncology
Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
Summary: This study investigated 363 patients with advanced lung adenocarcinoma harboring EGFR mutations and evaluated the efficacy of afatinib, erlotinib, and gefitinib according to mutation type. E19del and L858R mutations were associated with superior progression-free survival and overall survival compared to uncommon mutations. Afatinib showed significantly longer progression-free survival across all EGFR mutation types.
Article
Chemistry, Medicinal
Peng He, Ying Miao, Yue Sun, Aiwu Bian, Wangrui Jin, Jiangnan Ye, Huang Chen, Jia He, Yangrui Peng, Haijun Gu, Mingyao Liu, Zhengfang Yi, Yihua Chen
Summary: This study describes the design, synthesis, and structure-activity relationship studies of triaromatic heterocyclic derivatives as potent dual phosphorylation STAT3 inhibitors. The best compound 3h (HP590) was discovered with high inhibitory activity against p-Tyr(705) and p-Ser(727), resulting in the growth inhibition of gastric cancer both in vitro and in vivo.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Correction
Genetics & Heredity
Yuan Yuan, Young Seok Ju, Youngwook Kim, Jun Li, Yumeng Wang, Christopher J. Yoon, Yang Yang, Inigo Martincorena, Chad J. Creighton, John N. Weinstein, Yanxun Xu, Leng Han, Hyung-Lae Kim, Hidewaki Nakagawa, Keunchil Park, Peter J. Campbell, Han Liang
Correction
Genetics & Heredity
Yuan Yuan, Young Seok Ju, Youngwook Kim, Jun Li, Yumeng Wang, Christopher J. Yoon, Yang Yang, Inigo Martincorena, Chad J. Creighton, John N. Weinstein, Yanxun Xu, Leng Han, Hyung-Lae Kim, Hidewaki Nakagawa, Keunchil Park, Peter J. Campbell, Han Liang
Summary: A revised version of this paper has been published and can be accessed through a link at the top.
Article
Oncology
Michael Boyer, Mehmet A. N. Sendur, Delvys Rodriguez-Abreu, Keunchil Park, Dae Ho Lee, Irfan Cicin, Perran Fulden Yumuk, Francisco J. Orlandi, Ticiana A. Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te-Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck
Summary: The study showed that adding ipilimumab to pembrolizumab did not improve efficacy and was associated with greater toxicity in metastatic NSCLC patients.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Keunchil Park, Gee-Chen Chang, Giuseppe Curigliano, Wan-Teck Lim, Ross A. Soo, Miguel A. Molina-Vila, Valerie Cattan, Helene Darville, Eric Gandossi, Veronika Smutna, Isabelle Sudey, Santiago Viteri
Summary: The combination of gefitinib with S49076 showed limited anti-tumour activity with good tolerability in EGFR TKI-resistant NSCLC patients. The study did not reveal a clear trend in activity within specific molecular subsets due to the small number of eligible patients.
Article
Oncology
Hongsik Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
Summary: Plasma EGFR mutation tests are commonly used for NSCLC patients developing resistance to EGFR inhibitors. This study found that the detection rate of T790M in subsequent tests was influenced by the presence of sensitizing mutations in initial plasma tests. The low sensitivity of the plasma test for T790M suggests the need for follow-up tissue or plasma tests.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Sehhoon Park, Steve Olsen, Bo Mi Ku, Min-Sang Lee, Hyun-Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon-La Choi, Myung-Ju Ahn
Summary: This study analyzed the concordance of actionable genomic alterations in non-small cell lung cancer patients detected through circulating tumor DNA (ctDNA) and tissue sequencing. The results showed that ctDNA testing can identify additional actionable genomic alterations beyond tissue testing.
Article
Oncology
Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee, Joshua K. Sabari, Alexander Spira, Tsung-Ying Yang, Dong-Wan Kim, Ki Hyeong Lee, Rachel E. Sanborn, Jose Trigo, Koichi Goto, Jong-Seok Lee, James Chih-Hsin Yang, Ramaswamy Govindan, Joshua M. Bauml, Pilar Garrido, Matthew G. Krebs, Karen L. Reckamp, John Xie, Joshua C. Curtin, Nahor Haddish-Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho
Summary: Amivantamab demonstrates robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations, even after progression on platinum-based chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, Valeriy Breder, Dariusz M. Kowalski, Theodore Pollock, Evgeny Levchenko, Noemi Reguart, Alex Martinez-Marti, Baerin Houghton, Jean-Baptiste Paoli, Sufia Safina, Keunchil Park, Takefumi Komiya, Amy Sanford, Vishal Boolell, Hong Liu, Ayman Samkari, Steven M. Keller, Martin Reck
Summary: The study suggests promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC.
Article
Oncology
D. Ross Camidge, Teresa Moran, Ingel Demedts, Heidrun Grosch, Kathryn Mileham, Julian Molina, Oscar Juan-Vidal, Gerold Bepler, Jonathan W. Goldman, Keunchil Park, Johan Wallin, Sameera R. Wijayawardana, Xuejing Aimee Wang, Volker Wacheck, Egbert Smit
Summary: This Phase II study examined the use of emibetuzumab to overcome acquired resistance to erlotinib in NSCLC patients with high MET protein expression levels. The study found that emibetuzumab did not effectively reverse resistance to erlotinib, although some patients experienced clinical benefit.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Remi Veillon, Hiroshi Sakai, Xiuning Le, Enriqueta Felip, Alexis B. Cortot, Egbert F. Smit, Keunchil Park, Frank Griesinger, Christian Britschgi, Yi-Long Wu, Barbara Melosky, Shobhit Baijal, Gilberto de Castro Jr, Michaela Sedova, Karin Berghoff, Gordon Otto, Paul K. Paik
Summary: The study demonstrated the safety and tolerability of tepotinib in patients with MET exon 14 skipping non-small cell lung cancer. Adverse events were mostly mild/moderate and manageable, with few withdrawals.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Yuichiro Doki, Makoto Ueno, Chih-Hung Hsu, Do-Youn Oh, Keunchil Park, Noboru Yamamoto, Tatsuya Ioka, Hiroki Hara, Manabu Hayama, Masahiro Nii, Keiko Komuro, Mariko Sugimoto, Makoto Tahara
Summary: This study evaluated the safety, tolerability, and antitumor activity of durvalumab monotherapy and durvalumab plus tremelimumab combination therapy in Asian patients with biliary tract cancer, esophageal squamous cell carcinoma, or head and neck squamous cell carcinoma. The results demonstrated acceptable safety profiles and clinical benefit in these patients.
Article
Oncology
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin J. Solomon, Daniel Shao-Weng Tan, Guzman Alonso, Juergen Wolf, Keunchil Park, Koichi Goto, Victoria Soldatenkova, Sylwia Szymczak, Scott S. Barker, Tarun Puri, Aimee Bence Lin, Herbert Loong, Benjamin Besse
Summary: In this study, selpercatinib demonstrated durable and robust responses in both previously treated and treatment-naive patients with RET fusion-positive NSCLC, including intracranial activity.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi, Jhingook Kim, Keunchil Park
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Byoung Chul Cho, Herbert H. F. Loong, Chun-Ming Tsai, Man Lung P. Teo, Hye Ryun Kim, Sun Min Lim, Suyog Jain, Steve Olsen, Keunchil Park
Summary: Plasma-based next-generation sequencing provides timely and clinically informative mutational genomic profiling for advanced non-squamous NSCLC in East Asian patients.
Correction
Oncology
Makoto Nishio, Takashi Seto, Martin Reck, Edward B. Garon, Chao-Hua Chiu, Kiyotaka Yoh, Fumio Imamura, Keunchil Park, Jin-Yuan Shih, Carla Visseren-Grul, Bente Frimodt-Moller, Annamaria Zimmermann, Gosuke Homma, Sotaro Enatsu, Kazuhiko Nakagawa